- Study at Deakin
- Campus life
- Industry and community
- About Deakin
Type 2 diabetes is one of the major health burdens facing the world today. Diabetes is characterised by failure of the insulin producing cells in the pancreas (ß-cells). ß-cell failure is progressive, with patients requiring additional medications over time and eventually insulin injections. Current diabetes treatments cannot stop or slow the progression of ß-cell failure; therefore it is vital that new treatments be developed. Our project aims to generate a ß-cell gene expression signature and use it to screen for novel drugs that will not only effectively treat diabetes but also prevent ß-cell failure. These new improved drugs will improve quality of life and reduce the burden of type 2 diabetes for over 1 million Australians.
Now recruiting Honours and PhD students, please email expressions of interest to: firstname.lastname@example.org.
Dr Aston-Mourney completed her PhD in December 2007 at The University of Melbourne, Australia. During this time she examined the physiological and genetic basis of insulin hypersecretion and dysfunction in type 2 diabetes. She then broadened her interest into islet amyloid formation and degradation in type 2 diabetes during her postdoctoral fellowship with Professor Steven Kahn at the University of Washington, USA. In July 2011 Dr. Aston-Mourney returned to Australia where she is now investigating the gene expression signature of dysfunctional ß-cells and potential new drugs for the treatment of type 2 diabetes with Professor Ken Walder at the Metabolic Research Unit at Deakin University.
Dr Kathryn Aston-Mourney's Publications